CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Philippines

The industry analysis specialist, has released its latest report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Philippines. The report is an essential source of information and analysis regarding the healthcare, regulatory and reimbursement landscape in the Philippines. It identifies key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure in the country. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. This resource has been produced using data and information from proprietary databases, secondary research, and in-house analysis by GlobalDatas team of industry experts.
 

The population of the Philippines amounted to approximately 99.2 million in 2013, making it the 12th most populated country in the world. Population growth has primarily been due to a high birth rate and rising life expectancy. An increased elderly population is however a matter of concern for policy planners. The value of the pharmaceutical market in the country amounted to $4.3 billion in 2013, and it is expected to increase at a CAGR of 9.4% to reach approximately $8 billion in 2020.

 The positive trend in the healthcare market of the Philippines can be attributed primarily to the following factors:

 Generic substitution in both the public and private sectors, which has been a driver for the manufacture of generic drugs
 Increased expenditure on medicines by Local Government Units (LGUs)
 Government initiatives for the prevention and management of chronic diseases
 An improved and updated regulatory environment

 Scope

 This report provides information on the healthcare, regulatory, and reimbursement landscape in the Philippines, including the following:

 An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

 Profiles and SWOT analyses for major players in the pharmaceutical market (United Laboratories, Pfizer, GlaxoSmithKline, Novartis, Merck)

 An insightful review of the reimbursement and regulatory landscape, including details of the healthcare reimbursement process, regulatory agencies, and approval processes for new drugs and medical devices

 Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure, and healthcare expenditure

 An overview of the opportunities for and challenges facing growth in the healthcare market

 Reasons To Buy

 This report will enhance your decision-making capability by allowing you to:

 Develop business strategies based on a sound understanding of the trends shaping and driving the healthcare market in the Philippines
 Generate revenue based upon knowledge of key trends, reimbursement and regulatory policies, pharmaceutical market segments, and the companies likely to impact the healthcare market in the future
 Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
 Organize sales and marketing efforts by identifying the market categories and segments that present the greatest opportunities for consolidation, investment, and strategic partnership
 Identify, understand, and capitalize upon the opportunities and challenges in the Philippines healthcare market

Animal and Veterinary Vaccines Market

This Report focuses on "Animal and Veterinary Vaccines Market [Products (Livestock - Bovine, Companion - Canine, Poultry, Equine), Diseases (Rabies, Distemper, Foot & Mouth, Gumboro, Avian Influenza, Strangles), Technology (Live attenuated, DNA, Recombinant)] - Global Forecast to 2018"
 
The global animal vaccines market is in its growth phase and is estimated to be worth $5.8 billion in 2013. It is expected to grow at a healthy CAGR of 8.1% to reach $8.6 billion by 2018. The animal vaccines market is segmented on the basis of products, animal diseases, and technologies that are involved in developing vaccines for veterinary administration. The global animal vaccines market, by products, is further segmented into seven segments, namely, companion animal vaccines, livestock, poultry, porcine, equine, aquaculture, and other animal vaccines. In 2012, livestock vaccines and porcine vaccines were two of the largest segments, which accounted for 63% of the market share, globally. The livestock vaccines market is further segmented into bovine vaccines and small ruminant vaccines, whereas the companion animal vaccines market is further segmented into canine vaccines and feline vaccines.

By technology, the animal vaccines market is segmented on the basis of live attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. DNA vaccines demonstrate tremendous growth opportunities due to factors such as added thermo-stability, cost effectiveness, easy production, and rapid development against emerging diseases.

The factors responsible for the growth of the animal vaccine market include increasing incidences of zoonotic diseases in humans, growing prevalence of animal diseases, and increasing investments by government bodies, animal welfare associations, and leading players. Another factor that drives the growth in this space is the continuous innovations and introduction of new products in the market. Since 2012, more than 20 new products have been launched, presenting a huge potential for growth in this arena. However, increasing maintenance costs for vaccines and the shift towards vegetarian food by consumers will restrict the growth of the market to a certain extent. With the growing awareness of animal health in emerging economies, new entrants as well as established players have huge opportunities to introduce novel vaccines such as DNA and recombinant vaccines and to enter emerging countries.

Europe accounts for the largest share of the animal vaccines market, followed by North America. Both markets are reaching the maturity phase of their growth process, and will register mid single-digit growth rates for the next five years. The developing regions that include Asia, parts of Africa, and LATAM are expected to form the new revenue pockets for this market. These regions are poised to double their growth rates owing to the increasing investment opportunities for companies in these immature markets and the improving healthcare facilities for animals. Countries such as China, India, Australia, and Brazil will be major contributors to the growth of the market.

To encash the favorable conditions in developing economies and to stay ahead of the competition in the global market, a number of tier-I companies are investing in these countries. For instance, in April 2013, Lohmann Animal Health invested about $100 million to set up a poultry vaccine manufacturing plant in Taiwan.

Owing to high growth prospects in the aquaculture, companion, and equine vaccine which are estimated to double their growth rates during the forecast period, will observe huge investments in these segments from major players. For example in late 2011, Pfizer Animal Health invested $75 million to open an R&D centre in the U.S.

The market is dominated by tier I players and is fairly consolidated with the top five players contributing close to 70% of the share. New entrants face high barriers in entering this market as it is a capital-intensive industry with strict regulations. The major players in the global animal vaccines market are Pfizer (Zoetis) (U.S.), Merck (U.S.), Sanofi-Aventis (France), Bayer HealthCare (Germany), Virbac (France), Novartis (Switzerland), Boehringer Ingelheim (Germany), Heska Corporation (U.S.), Bioniche Animal Health Canada Inc. (Canada), and Ceva (France).

Power Transmission and Distribution (T&D) In Asia-Pacific - Infrastructure, Investment and Regulation Analysis

Summary

Power Transmission and Distribution (T&D) In Asia-Pacific - Infrastructure, Investment and Regulation Analysis gives detailed information on the transmission and distribution market in the Asia Pacific region, focusing on countries China, India, Indonesia, Australia, Japan and New Zealand. The report covers all the six countries for the transmission and distribution market. T&D infrastructure, investment analysis, drivers, restraints, and regulation analysis is given for each of the six countries.


   Scope

 - The report provides detailed analysis of the transmission and distribution market in different countries. Its scope includes the study of different countries such as China, India, Indonesia, Japan, Australia and New Zealand.
 - Information related to power supply structure in the countries.
 - Analysis of T&D market related to network lines (in Ckm), capacity (in MVA) and substations (units) for the countries.
 - Information related to smart grid and power imports and exports in the countries.
 - T&D investment planned during the forecast period in the countries.
 - Key regulations influencing the T&D market in these countries.

 Reasons to buy

 The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to -
 - Facilitate decision-making based on historic and forecast data related to T&D capacity, line length and substations in the China, India, Indonesia, Japan, Australia and New Zealand.
 - Refine business strategies with a complete understanding of the trends and developments shaping the T&D markets in the above mentioned key countries.
 - Evaluate opportunities in promising T&D markets to quantify potential returns on investment.

Global Radiation Therapy Equipment Market

Radiation therapy equipment is used to perform radiation therapy, also known as radiotherapy or radiation oncology, which is a procedure used in the treatment of cancer. It involves delivering high doses of radiation consisting of photons, electrons or gamma rays to kill cancer cells and reduce the rate at which the cancerous cells multiply by damaging the DNA inside the tumor cells. Radiation therapy is used to treat cancers of the head and neck, bladder, and lung as well as Hodgkins disease. Radiation therapy can be administered in several ways. The type of therapy prescribed by oncologists depends on factors such as the type of cancer, the stage of the cancer, the size of the tumor, the position of the tumor in the body, the age of the patient, and the patients medical history. Radiation therapy can either be given independently or in conjunction with other cancer treatments such as surgery and chemotherapy.
TechNavios analysts forecast the Global Radiation Therapy Equipment market will grow at a CAGR of 6.04 percent over the period 2013-2018.

Covered in this Report

• The Global Radiation Therapy Equipment market can be divided into three segments: Linear Accelerators, Treatment Planning Systems, and Radiation Therapy Simulators.
• The Global Radiation Therapy Equipment Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Radiation Therapy Equipment market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
Americas
EMEA
APAC

Key Vendors
Accuray Inc.
Elekta AB
Siemens Healthcare
Varian Medical Systems Inc.

Other Prominent Vendors
Best Theratronics Ltd.
Brainlab AG
C.R. Bard Inc.
Eckert & Ziegler BEBIG
GE Healthcare Ltd.
Hitachi America Ltd.
Ion Beam Applications SA
Philips Healthcare
RaySearch Laboratories AB